Current Pharmaceutical Design
Title: Preface The Urokinase-type Plasminogen Activator System in Cancer and other Pathological Conditions: Introduction and Perspective [Hot Topic: The Urokinase-type Plasminogen Activator System in Cancer (Executive Editor : S. Rosenberg)].
Volume: 9 Issue: 19
Author(s): Steven Rosenberg
Affiliation:
Export Options
About this article
Cite this article as:
Rosenberg Steven, Preface The Urokinase-type Plasminogen Activator System in Cancer and other Pathological Conditions: Introduction and Perspective [Hot Topic: The Urokinase-type Plasminogen Activator System in Cancer (Executive Editor : S. Rosenberg)]., Current Pharmaceutical Design 2003; 9 (19) . https://dx.doi.org/10.2174/138161281030900iv
DOI https://dx.doi.org/10.2174/138161281030900iv |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Defensin Participation in Innate and Adaptive Immunity
Current Pharmaceutical Design Clearance of Beta-Amyloid in the Brain
Current Medicinal Chemistry ‘Treat to Target’ in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy
Current Drug Targets Discovery and Development of Purine-Scaffold Hsp90 Inhibitors
Current Topics in Medicinal Chemistry Properties of the Mesenchymal Endometriotic Stem Cell in the Context of the Immune System and Analysis of its Role in Endometriosis
Recent Patents on Regenerative Medicine Smart Stimuli Sensitive Nanogels in Cancer Drug Delivery and Imaging: A Review
Current Pharmaceutical Design Computer Modeling of Brain Tumor Growth
Mini-Reviews in Medicinal Chemistry microRNAs Downregulation in Cancer is Associated with Guanine Enrichment in the Terminal Loop Sequences of their Precursors
MicroRNA Gemcitabine Interacts with Carbonate Apatite with Concomitant Reduction in Particle Diameter and Enhancement of Cytotoxicity in Breast Cancer Cells
Current Drug Delivery Proline Oxidase (POX) as A Target for Cancer Therapy
Current Drug Targets Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry Requirements and Perspectives for Integrating Metabolomics with other Omics Data
Current Metabolomics (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) The Role of MDR1 Genetic Polymorphisms in Interindividual Variability in P-glycoprotein Expression and Function
Current Drug Metabolism Synthesis of Graphene Oxide-Silver Nanoparticle Nanocomposites: An Efficient Novel Antibacterial Agent
Current Nanoscience The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Anticancer Actions of Omega-3 Fatty Acids - Current State and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Protective Role of Natural Products in Cisplatin-Induced Nephrotoxicity
Mini-Reviews in Medicinal Chemistry The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets